ICU Medical, Inc. $ICUI Shares Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 22.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,875 shares of the medical instruments supplier’s stock after acquiring an additional 1,431 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in ICU Medical were worth $1,041,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Kirr Marbach & Co. LLC IN grew its stake in shares of ICU Medical by 0.6% during the 2nd quarter. Kirr Marbach & Co. LLC IN now owns 36,103 shares of the medical instruments supplier’s stock worth $4,771,000 after purchasing an additional 233 shares during the period. State of Alaska Department of Revenue boosted its holdings in ICU Medical by 7.8% during the second quarter. State of Alaska Department of Revenue now owns 14,624 shares of the medical instruments supplier’s stock worth $1,932,000 after buying an additional 1,057 shares in the last quarter. Oliver Luxxe Assets LLC grew its position in ICU Medical by 2.1% during the second quarter. Oliver Luxxe Assets LLC now owns 10,777 shares of the medical instruments supplier’s stock valued at $1,424,000 after buying an additional 219 shares during the period. Moody National Bank Trust Division increased its holdings in ICU Medical by 0.9% in the second quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock valued at $1,421,000 after buying an additional 93 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of ICU Medical in the first quarter worth about $972,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $122.07 on Friday. The business’s fifty day simple moving average is $125.22 and its 200-day simple moving average is $131.87. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The firm has a market cap of $3.01 billion, a PE ratio of -80.31 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business had revenue of $543.57 million during the quarter, compared to analysts’ expectations of $543.33 million. During the same period last year, the business earned $1.56 earnings per share. The business’s revenue for the quarter was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director David C. Greenberg purchased 1,200 shares of the stock in a transaction dated Wednesday, August 27th. The stock was acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at approximately $1,006,303.20. This represents a 17.75% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Vivek Jain acquired 21,929 shares of the company’s stock in a transaction dated Thursday, August 14th. The stock was purchased at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the purchase, the chief executive officer directly owned 130,149 shares of the company’s stock, valued at approximately $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Piper Sandler lifted their price target on ICU Medical from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research report on Saturday, September 27th. Finally, Raymond James Financial cut their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $181.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.